Total n = 30

Age, years (median)

58 (40-76)

Sex

Male

23 (76.6%)

Female

7 (23.4%)

Performance Status

0-1

29 (96.6%)

2

1 (3.4%)

Smoking

Never smoker

1 (3.4%)

Former smoker

10 (33.3%)

 Smoker

19 (63.3%)

Histology

Adenocarcinoma

20 (63.6%)

Squamous Carcinoma

6 (20%)

Sarcomatoid

2 (6.7%)

Large Cell

2 (6.7%)

1

 1 (3.5%)

2

13 (46.4%)

T stage

3

5 (17.8%)

4

9 (32.1%)

N stage

0

5 (16.6%)

1

4 (13.3%)

2

20 (63.6%)

3

1 (3.3%)

Site of Metastases

Brain

14 (46.6%)

Lung

7 (23.3%)

Bone

6 (20%)

Adrenal

2 (6.6%)

Lymph Node

1 (3.3%)

Number of Metastases

1

23 (76.6%)

2

5 (16.6%)

3

2 (6.6%)

Chemotherapy regimen

CDDP-Pemetrexed

11 (36.6%)

CDDP-VNB

12 (40%)

CDDP-Gemcitabine

2 (6.6%)

CDDP-Docetaxel

2 (6.6%)

Carboplatin-Paclitaxel

3 (9.9%)

Radiotherapy

Concurrent

18 (60%)

Sequential

12 (40%)

Treatment of Metastases

Surgery

4 (13.3%)

Stereotactic RT

16 (53.3%)

Radiotherapy

8 (26.6%)

Radiofrequency

1 (3.3%)

None^*

1 (3.3%)^*